Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations

Documenti analoghi

• Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
  di: Lin L, et al.
  Pubblicazione: (2020-09-01)
• Response to Afatinib in a Patient with Non-Small Cell Lung Cancer Harboring HER2 R896G Mutation: A Case Report
  di: Lin, Ling, et al.
  Pubblicazione: (2019)
• Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
  di: Zöchbauer-Müller, Sabine, et al.
  Pubblicazione: (2021)
• Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
  di: Zhang, Shannon S, et al.
  Pubblicazione: (2021)
• Anti-tumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 Insertions
  di: Floc’h, Nicolas, et al.
  Pubblicazione: (2018)